Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
Categories: Agents for Dermatitis, Excluding CorticosteroidsIMM-101
go.drugbank.com/drugs/DB15850InvestigationalIt has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).
Mebeverine
go.drugbank.com/drugs/DB12554ApprovedInvestigationalWithdrawnMebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.
Categories: Drugs for Functional Gastrointestinal DisordersAtazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalAtazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseZandatrigine
go.drugbank.com/drugs/DB19051InvestigationalZandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).
Benzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigational[L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564] … Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason for treatment
Oral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalThe polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are … Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with
HLX70
go.drugbank.com/drugs/DB16509InvestigationalThe condition targeted by HLX70 in this study is COVID-19. … HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics
Categories: Experimental Unapproved Treatments for COVID-19Ularitide
go.drugbank.com/drugs/DB05034InvestigationalUlaritide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. … Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. … [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Categories: Antidepressive Agents Indicated for Depression